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Complete Remission of Nephrotic Syndrome
of Hepatitis B Virus-associated Membranous
Glomerulopathy After Lamivudine
Monotherapy
Tang-Wei Chuang,1 Chao-Hung Hung,1* Shun-Chen Huang,2 Chuan-Mo Lee1
We present the case of a 22-year-old male with chronic hepatitis B virus (HBV) infection, who developed
nephrotic syndrome and had complete remission after lamivudine monotherapy. Renal biopsy showed
membranous glomerulopathy, and the serum titer of HBV DNA increased to 1,130,000 copies/mL. As symp-
tomatic therapy with angiotensin converting enzyme inhibitors did not improve the nephrotic syndrome,
lamivudine 100 mg per day was started. His alanine aminotransferase level normalized 2 months after
treatment, then hepatitis B e antigen seroconversion developed and serum HBV DNA became undetectable.
His proteinuria improved subsequently and his leg edema disappeared completely 6 months after treat-
ment. Neither hepatitis nor nephrotic syndrome had relapsed by month 13 when he came for follow-up.
This suggests that lamivudine monotherapy may induce and maintain complete remission of membranous
glomerulopathy associated with hepatitis B. [J Formos Med Assoc 2007;106(10):869–873]
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CASE REPORT
According to clinical, epidemiologic and immu-
nologic evidence, chronic hepatitis B virus (HBV)
infection is strongly associated with the occurrence
of membranous glomerulopathy (MN), particu-
larly in children.1 The majority of pediatric pa-
tients with HBV-related MN have a good prognosis
in terms of the preservation of renal function, and
there is a high rate of spontaneous remission.2 In
contrast, the clinical course of HBV-related MN
in adults is not benign. Regardless of treatment,
this disease has a slow but relentlessly progres-
sive course in approximately one third of adult
patients.3
Steroids and other immunosuppressive
therapies that are the mainstay of treatment for
idiopathic forms of MN may cause more harm
than good by enhancing viral replication and
precipitating hepatitis flares in HBV-related MN.
Interferon (IFN)-α, while reported to be useful
in children, has produced disappointing results
in Chinese adult subjects.3 Recently, lamivu-
dine, a nucleoside analog inhibitor of HBV DNA
polymerase, has been shown to have advan-
tages over IFN for HBV treatment because of its
having fewer side effects and an oral route of
administration.
Here, we report the case of an adult patient
with chronic hepatitis B who developed MN with
nephrotic syndrome and who experienced com-
plete remission after lamivudine monotherapy.
Case Report
A 22-year-old Taiwanese male patient who had a
history of chronic HBV infection lasting for several
years was regularly followed-up at the local med-
ical clinic. He was found to be positive for hepa-
titis B surface antigen (HBsAg) and hepatitis B 
e antibody (anti-HBe Ab), and negative for hepa-
titis B e antigen (HBeAg). He had an increased
serum level of aspartate aminotransferase (AST) of
268 U/L and alanine aminotransferase (ALT) of
239 U/L in May 2003. Three months later, due 
to progressive edematous changes in bilateral legs,
he was referred to our outpatient department.
Laboratory analyses showed the following: serum
AST of 99U/L, ALT of 119U/L, creatinine of 0.9mg/
dL, and decreased albumin level of 1.6 g/dL. Serol-
ogically, his anti-HBe Ab was positive. His HBeAg,
immunoglobulin (Ig) M antibody to hepatitis B
core, IgM antibody to hepatitis A virus, and anti-
body to hepatitis C virus were all negative. His
serum HBV DNA as determined by sensitive poly-
merase chain reaction assay (COBAS Amplicor
HBV Monitor; Roche Diagnostics, Branchburg,
NJ, USA) was 1,130,000 copies/mL. Urinalysis
showed proteinuria 500 mg/dL by dipstick. His
renal and abdominal ultrasound examinations
were normal.
He was admitted to our hospital for a renal
biopsy in September 2003. Physical examination
was unremarkable except for the extremities which
showed severe pitting edema. A repeat data collec-
tion showed decreased albumin level of 1.1 g/dL,
high cholesterol level of 370 mg/dL and urine total
protein loss of 6.0g/day. His renal biopsy displayed
diffusely thickened and rigid capillary walls. Spikes
were identified in a few segments by silver stain.
On immunofluorescence study, IgG, C3 and C4
were positive along the capillary loops in a gran-
ular pattern. IgM was also present, but to a lesser
intensity. On electron microscopy, the glomeruli
showed diffuse foot process effacement of the ep-
ithelial cells. The capillary loops were irregularly
thickened by many small and large electron-dense
deposits on the subepithelial side of the base-
ment membrane, compatible with membranous
nephropathy stage II to III (Figure 1). Fosinopril
10 mg/day was given initially, which was then
changed to valsartan 40 mg/day and albumin 
infusion combined with diuretic therapy (25 mg
spironolactone, three times daily) for the edema
in his legs.
In October 2003, his bilateral leg edema per-
sisted without any clinical improvement. Repeat
data collection showed that his AST and ALT levels
were still elevated (128 U/L and 84 U/L, respec-
tively), and HBeAg was positive. Serum albumin
had decreased to 0.7g/dL. He began treatment with
lamivudine 100 mg/day after giving informed con-
sent. His ALT levels gradually decreased and nor-
malized 2 months after the start of treatment, in
which HBeAg seroconversion developed and his
serum HBV DNA became negative (< 200 copies/
mL). His serum albumin level gradually increased
and was > 3.0 g/dL after 9 months of therapy. The
pitting edema in both legs disappeared completely
6 months after lamivudine treatment, and diuret-
ics were not necessary thereafter. Lamivudine was
discontinued after 18 months of therapy. By month
13 after lamivudine treatment had been stopped,
the patient remained free of edema, with normal
ALT, albumin and cholesterol levels and no de-
tectable HBV DNA in his serum. His daily urine
protein loss had decreased to 0.6 g/day and 0.02 g/
day at the end of treatment and at follow-up, 
respectively (Figure 2).
Discussion
A variety of extrahepatic manifestations is ob-
served in patients with both acute and chronic
viral hepatitis. A previous study has shown that
approximately 16% of chronic hepatitis B pa-
tients have clinical extrahepatic manifestations,
mainly sensorimotor deficiency (5%), sicca syn-
drome (3%), myalgia (3%), glomerulonephritis
(3%), and arthralgia-arthritis (3%).4 MN is an
uncommon but well-documented extrahepatic
manifestation of HBV infection. The diagnosis of
HBV-associated MN is usually established by sero-
logic evidence of persistent HBV infection, the
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Figure 1. (A) Glomeruli show diffusely thickened and rigid capillary walls (hematoxylin & eosin, 66×). (B) Silver stain shows
spikes in a few segments (periodic acid methenamine silver stain, 330×). (C) Electron microscopy shows irregularly thick-
ened capillary walls with many small and large electron-dense deposits on the subepithelial side of the basement mem-
brane (4000×). (D) Viral-like particles (arrows) appearing as clusters of round to ovoid structures, 10–30 nm in diameter
and of varying density, were seen in some electron-dense deposits.
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Figure 2. Serial results of alanine aminotransferase (ALT), albumin and total daily protein loss (TDPL) with lamivudine
treatment.
presence of immune complex deposits on kidney
biopsy, and by the demonstration of glomerular
deposits containing one or more HBV-related anti-
gens (HBsAg and hepatitis B core antigen) on im-
munohistochemical study. In our patient, although
special stains of HBV antigen was not performed,
we used electron microscopy and found viral-like
particles appearing as clusters of round to ovoid
structures of 10–30 nm in diameter and varying
density distributed within the glomerular capillary
basement membrane. In addition, active HBV in-
fection during the course of disease progression
and evidence of the reversibility of the renal disease
concomitant with a decrease in viral load suggested
a direct link between MN and HBV infection.
The clinical manifestations of HBV-associated
MN in pediatric and adult patients tend to be
different. Pediatric chronic HBV carriers are not
infrequently asymptomatic and HBV-associated
nephropathy is detected by routine urine and
serologic screening.5 Unlike childhood disease
in which there is a high rate of spontaneous re-
mission,2 adults with HBV-associated MN typically
develop a progressive disease.3 Therefore, there is
a pressing need to develop an effective treatment
for the latter. To date, the most experience with
antiviral treatment for HBV-associated MN in
adults has been limited to trials with IFN, and
the results have been disappointing in Chinese
subjects.3,6–8 Furthermore, some disadvantages of
IFN include its expense, the requirement for sub-
cutaneous injection, and frequent side effects such
as fever, headache, malaise, myalgia, as well as
blood dyscrasias and neuropsychiatric disturbance.
In contrast, the incidence of adverse effects with
lamivudine is considered to be similar to that of
placebo.
Lamivudine therapy is safe and effective in
chronic hepatitis B patients in terms of HBV DNA
suppression, ALT normalization and improvement
in histology.9 Lamivudine treatment has been suc-
cessful in adults with HBV-associated polyarteritis
nodosa and other immune complex diseases.10,11
Recently, a few case reports and only one cohort
study with small case numbers have shown that
lamivudine treatment might remit HBV-associated
MN successfully.12–16 In our patient, normalization
of ALT levels and HBeAg seroconversion developed
2 months after the start of treatment, and nephrotic
symptoms such as leg edema disappeared after 
6 months of therapy. His daily urine protein ex-
cretion decreased from 6 g at baseline to 0.6 g by
the end of treatment, and this continued to im-
prove to the end of the follow-up period (0.02 g/
day). The response in our patient is comparable
to that seen in other previously reported cases,
suggesting that recovery of nephrosis takes a lon-
ger time than hepatitis activity in HBV-associated
MN.12–16 On the other hand, in contrast to child-
hood disease in which there is a rapid remission
of proteinuria, adults with HBV-associated MN
recover slowly.12–16
Although lamivudine therapy successfully re-
mitted the HBV-related membrane nephropathy,
several issues need to be further clarified. First, the
duration of lamivudine therapy remains unre-
solved. It is reasonable to maintain patients on
long-term lamivudine treatment because of the
high relapse rate on a short course.17 Second,
a potential limitation of prolonged treatment
with lamivudine is the emergence of drug-resistant
strains due to the induction and selection of
HBV variants with mutations at the tyrosine-
methionine-aspartate-aspartate (YMDD) motif
of DNA polymerase.18 One agent that might be
considered in case of lamivudine resistance is
adefovir dipivoxil, which is effective against both
lamivudine-resistant HBV mutants as well as wild-
type HBV.19 However, this agent is potentially
nephrotoxic and there are no data on its efficacy
in HBV-related MN. Third, whether lamivudine
therapy is helpful in HBV-related MN cases in
which ALT levels are normal and there is no hep-
atitis activity or hepatitis B viremia remains unclear.
Further studies in a larger cohort of patients are
needed to clarify these important issues.
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